Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 8562528, 8 pages
http://dx.doi.org/10.1155/2016/8562528
Research Article

The Therapeutic Effects of the Chinese Herbal Medicine, Lang Chuang Fang Granule, on Lupus-Prone MRL/lpr Mice

Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

Received 19 November 2015; Revised 24 January 2016; Accepted 1 February 2016

Academic Editor: Isabel Andújar

Copyright © 2016 Kai-Peng Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Lisnevskaia, G. Murphy, and D. Isenberg, “Systemic lupus erythematosus,” The Lancet, vol. 384, no. 9957, pp. 1878–1888, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. S. Lim and C. Drenkard, “Epidemiology of lupus: an update,” Current Opinion in Rheumatology, vol. 27, no. 5, pp. 427–432, 2015. View at Publisher · View at Google Scholar
  3. M. J. Podolska, M. H. Biermann, C. Maueröder, J. Hahn, and M. Herrmann, “Inflammatory etiopathogenesis of systemic lupus erythematosus: an update,” Journal of Inflammation Research, vol. 8, pp. 161–171, 2015. View at Publisher · View at Google Scholar
  4. E. Zimlichman, J. Rothschild, Y. Shoenfeld, and G. Zandman-Goddard, “Good prognosis for hospitalized SLE patients with non-related disease,” Autoimmunity Reviews, vol. 13, no. 11, pp. 1090–1093, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. O. P. Rekvig and J. Van der Vlag, “The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved,” Seminars in Immunopathology, vol. 36, no. 3, pp. 301–311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Squatrito, G. Emmi, E. Silvestri et al., “Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside,” Autoimmunity Highlights, vol. 5, no. 2, pp. 33–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Wallace, “The evolution of drug discovery in systemic lupus erythematosus,” Nature Reviews Rheumatology, vol. 11, no. 10, pp. 616–620, 2015. View at Publisher · View at Google Scholar
  8. M. Relle, J. Weinmann-Menke, E. Scorletti, L. Cavagna, and A. Schwarting, “Genetics and novel aspects of therapies in systemic lupus erythematosus,” Autoimmunity Reviews, vol. 14, no. 11, pp. 1005–1018, 2015. View at Publisher · View at Google Scholar
  9. T. Patavino and D. M. Brady, “Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus,” Alternative Medicine Review, vol. 6, no. 5, pp. 460–471, 2001. View at Google Scholar · View at Scopus
  10. T. Ito, N. Seo, H. Yagi et al., “Unique therapeutic effects of the Japanese-Chinese herbal medicine, Sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice,” Journal of Dermatological Science, vol. 28, no. 3, pp. 198–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. Y.-N. Liao, C.-S. Liu, T.-R. Tsai et al., “Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up,” Kaohsiung Journal of Medical Sciences, vol. 27, no. 7, pp. 251–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. L. L. D. Zhong, Z. X. Bian, J. H. Gu et al., “Chinese herbal medicine (Zi Shen Qing) for mild-to-moderate systematic lupus erythematosus: a pilot prospective, single-blinded, randomized controlled Study,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 327245, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. C.-Y. Liu, W.-H. Wu, T.-P. Huang, T.-Y. Lee, and H.-H. Chang, “A novel model for exploring the correlation between patterns and prescriptions in clinical practice of traditional Chinese medicine for systemic lupus erythematosus,” Complementary Therapies in Medicine, vol. 22, no. 3, pp. 481–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. T.-Y. Lee and H.-H. Chang, “Longdan Xiegan Tang has immunomodulatory effects on CD4+CD25+ T cells and attenuates pathological signs in MRL/lpr mice,” International Journal of Molecular Medicine, vol. 25, no. 5, pp. 677–685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Yang, R.-G. Ye, C.-C. Pei, G.-X. Liu, and Y.-J. Li, “Observational study of Lang Chuang Fang and immunosuppressants in the treatment of lupus nephritis,” Chinese Medicine, vol. 35, no. 6, pp. 45–46, 2000. View at Google Scholar
  16. Y.-B. Zhou, R.-G. Ye, Y.-J. Li et al., “The effects of traditional Chinese medicine Lang Chuang Fang on CD134/CD134L expression in the spleen of lupus-like BXSB mice,” Chinese Journal of Integrated Traditional and Western Nephrology, vol. 7, no. 5, pp. 254–257, 2006. View at Google Scholar
  17. M. Liang, Y.-J. Li, X. Yang et al., “The effects of Lang Chuang Fang on RANTES expression in the kidney of lupus-like mice,” Chinese Journal of Immunology, vol. 18, no. 9, pp. 631–635, 2002. View at Google Scholar
  18. Y.-B. Zhou, Y.-H. Wu, Y.-J. Li, and C.-M. Xie, “The effects of traditional Chinese medicine Lang Chuang Fang on immune system and lymphocyte subsets in the spleen of lupus-like BXSB mice,” Chinese Journal of Pathophysiology, vol. 22, no. 3, pp. 551–554, 2006. View at Google Scholar
  19. Q. Chen, Methodology on Chinese Medicinal Pharmacology, People's Medical Publishing House, Beijing, China, 1994 (Chinese).
  20. Y.-W. Wu, S.-J. He, B.-X. Bai et al., “Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation,” Cellular & Molecular Immunology, 2015. View at Publisher · View at Google Scholar
  21. C. Mohan and C. Putterman, “Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis,” Nature Reviews Nephrology, vol. 11, no. 6, pp. 329–341, 2015. View at Publisher · View at Google Scholar
  22. K. A. Tshilela, H. Ikeuchi, T. Matsumoto et al., “Glomerular cytokine expression in murine lupus nephritis,” Clinical and Experimental Nephrology, vol. 20, no. 1, pp. 23–29, 2016. View at Publisher · View at Google Scholar
  23. F. Lin, X.-R. Luo, A. Tsun, Z.-Y. Li, D. Li, and B. Li, “Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation,” International Immunopharmacology, vol. 28, no. 2, pp. 859–865, 2015. View at Publisher · View at Google Scholar
  24. I. Andújar, M. C. Recio, T. Bacelli, R. M. Giner, and J. L. Ríos, “Shikonin reduces oedema induced by phorbol ester by interfering with IκBα degradation thus inhibiting translocation of NF-κB to the nucleus,” British Journal of Pharmacology, vol. 160, no. 2, pp. 376–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Li, F.-G. Yan, R. Wang, H. Zhou, and L. Liu, “Shikonin suppresses human T lymphocyte activation through inhibition of IKKβ activity and JNK phosphorylation,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 379536, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Yang, J. Wang, Q. Yang et al., “Shikonin inhibits the lipopolysaccharide-induced release of HMGB1 in RAW264.7 cells via IFN and NF-κB signaling pathways,” International Immunopharmacology, vol. 19, no. 1, pp. 81–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. X.-C. Wang, J. Feng, F. Huang et al., “Effects of Shikonin isolated from Zicao on lupus nephritis in NZB/W F1 mice,” Biological and Pharmaceutical Bulletin, vol. 32, no. 9, pp. 1565–1570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Lei, J. Luo, L. Tong et al., “Quercetin binds to calcineurin at a similar region to cyclosporin A and tacrolimus,” Food Chemistry, vol. 127, no. 3, pp. 1169–1174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-K. Kang, D. Ecklund, M. Liu, and S. K. Datta, “Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells,” Arthritis Research & Therapy, vol. 11, no. 2, article R59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Li and I. M. Verma, “NF-κB regulation in the immune system,” Nature Reviews Immunology, vol. 2, no. 10, pp. 725–734, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Zheng, R. Sinniah, and S. I.-H. Hsu, “In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy,” Virchows Archiv, vol. 448, no. 2, pp. 172–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Kalergis, M. I. Iruretagoyena, M. J. Barrientos et al., “Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus,” Immunology, vol. 128, no. 1, supplement, pp. 306–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Sequeira, G. Boily, S. Bazinet et al., “sirt1-null mice develop an autoimmune-like condition,” Experimental Cell Research, vol. 314, no. 16, pp. 3069–3074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Zhang, S.-M. Lee, S. Shannon et al., “The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice,” The Journal of Clinical Investigation, vol. 119, no. 10, pp. 3048–3058, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C.-M. Hao and V. H. Haase, “Sirtuins and their relevance to the kidney,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1620–1627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Yoh, K. Itoh, A. Enomoto et al., “Nrf2-deficient female mice develop lupus-like autoimmune nephritis,” Kidney International, vol. 60, no. 4, pp. 1343–1353, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Jiang, F. Tian, H.-T. Zheng et al., “Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response,” Kidney International, vol. 85, no. 2, pp. 333–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. P.-Y. Tsai, S.-M. Ka, J.-M. Chang et al., “Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation,” Free Radical Biology and Medicine, vol. 51, no. 3, pp. 744–754, 2011. View at Publisher · View at Google Scholar · View at Scopus